Anita Kulukian
0009-0001-5590-706X
Publication & Citation Trends
Most Cited Works
Publications
56 total
HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer PDF
Cited by 17
OpenAlex
Abstract PS10-08: Tucatinib potentiates the activity of the antibody-drug conjugate T-DM1 in preclinical models of HER2-positive breast cancer
Cited by 5
OpenAlex
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Cited by 208
OpenAlex
Abstract P1-18-09: Tucatinib, a HER2-selective tyrosine kinase inhibitor, increases the anti-tumor activity of trastuzumab antibody-drug conjugates in preclinical models of HER2+ breast cancer
Cited by 6
OpenAlex
A Small-Molecule Pan-Id Antagonist Inhibits Pathologic Ocular Neovascularization PDF
Cited by 56
OpenAlex
Author Correction: Inflammatory memory sensitizes skin epithelial stem cells to tissue damage PDF
Cited by 6
OpenAlex
Inflammatory memory sensitizes skin epithelial stem cells to tissue damage PDF
Cited by 718
OpenAlex
Research Topics
HER2/EGFR in Cancer Research
(42)
Monoclonal and Polyclonal Antibodies Research
(27)
Advanced Breast Cancer Therapies
(12)
Lung Cancer Treatments and Mutations
(11)
Microtubule and mitosis dynamics
(7)
Frequent Co-Authors
Affiliations
Program for Appropriate Technology in Health
Memorial Sloan Kettering Cancer Center
Howard Hughes Medical Institute
University of California, San Diego
Seagen (Canada)